Clinical Trials Logo

Clinical Trial Summary

This is a randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Bludigo™ (indigotindisulfonate Sodium Injection, USP) 0.8% when used as an aid in the determination of ureteral patency. Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure, age 18 to 85 years inclusive, will be screened for participation. Screening will occur within 30 days before study drug administration (Day of Surgery). After signing the informed consent, review of inclusion and exclusion criteria will be performed, the collection of concomitant medications, medical history, physical examination, baseline laboratory testing, 12-lead ECG, and vital sign measurements will be completed during the screening visit. On the day of surgery (Day 1) subjects will be evaluated for eligibility for randomization. Eligible subjects will be stratified by BMI (<30.0 kg/m2or ≥ 30.0 kg/m2) and randomized in a 1:1 ratio to receive a dose of either Bludigo™ high dose (5.0 mL) or Bludigo™ low dose (2.5 mL). Each randomized subject will serve as his/her own control (i.e., intra-patient controlled) by receiving a dose of normal saline prior to receiving the randomized Bludigo™ dose. All treated subjects will have a follow-up visit 7 to 30 days (± 2 days) after the procedure. A final telephone follow-up call will occur on Day 30 (± 2 days) in subjects who have the follow-up visit before Day 28. Safety assessments will include monitoring of AEs during and post the procedure, clinical laboratory tests, 12-Lead ECG, and vital sign measurements.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06054880
Study type Interventional
Source Prove pharm
Contact Michelle Boytim, P.hD.
Phone 610-850-7115
Email michelle.boytim@provepharm.com
Status Recruiting
Phase Phase 4
Start date October 12, 2023
Completion date January 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05640115 - Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent Early Phase 1
Completed NCT03937505 - A Safety and Efficacy Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy Phase 2
Not yet recruiting NCT06448143 - Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Pediatric Patients Phase 3
Completed NCT05769257 - A Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal Surgery Phase 2
Recruiting NCT06278753 - Comparison of Standard Cystoscopy With Carbon Dioxide Cystoscopy
Recruiting NCT05954767 - IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery Phase 3
Completed NCT04228445 - 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency Phase 3
Recruiting NCT06085183 - Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Patient's With Renal Impairment Phase 4
Completed NCT03387410 - Ureter Identification With IRDye 800BK Phase 1/Phase 2